Autres langues DiaMedica Therapeutics Inc.

Actions

DMAC

CA25253X2077

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 14/09/2026			Varia. 5j.	Varia. 1 janv.
6,550 ^USD	+1,24%		-2,96%	-17,71%

11/08	Transcript : DiaMedica Therapeutics Inc., Q2 2026 Earnings Call, Aug 11, 2026
10/08	DiaMedica Therapeutics Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

02/09	DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
10/08	DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
04/08	DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
17/07	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/06	Diamedica Therapeutics Doses First Patients in Phase 2 Trial of DM199 for Treatment of Fetal Growth Restriction
23/06	DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial
23/06	DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
16/06	DiaMedica Therapeutics Inc. Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
16/06	DiaMedica Therapeutics Receives US FDA Guidance on DM199 Nonclinical Requirements
16/06	DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
27/05	DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
20/05	DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment
20/05	Diamedica Therapeutics announces 75% enrollment milestone in Remedy2 phase 2/3 acute ischemic stroke trial
20/05	DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
20/05	DiaMedica Therapeutics Inc. Announces 75% Enrollment Milestone In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
12/05	DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
06/05	DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
30/04	DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
21/04	RedChip's Biotech Virtual Investor Conference Replays Now Available
07/04	RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
30/03	DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
30/03	DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
23/03	DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026